A new vector system with inducible E2a cell line for production of higher titer and safer adenoviral vectors

Virology

Volumn 275, Issue 2, 2000, Pages 348-357

  Zhou, Heshan ^a,b   Beaudet, Arthur L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; GLYCOPROTEIN E1; TETRACYCLINE; TRANSCRIPTION FACTOR E2A; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CELL LINE; CONTROLLED STUDY; GENE DELETION; GENE THERAPY; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAFETY; STRAIN DIFFERENCE; VACCINATION; VIRUS TITRATION;

EID: 0034734772     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0515     Document Type: Article

References (44)

1. Next-generation adenoviral vectors: New and improved
2. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol
3. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3
4. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
5. Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response
6. Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12
7. New helper cells and matched early region 1-deletion adenovirus vectors prevent generation of replication-competent adenoviruses
8. Who's afraid of replication-competent adenoviruses
9. A cell line for high-yield production of E1-deleted adenovirus vectors without the emergence of replication-competent virus
10. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy
11. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy
12. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
13. Covalently closed circles of human adenovirus DNA are infectious
14. Manipulation of adenovirus vectors
15. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
16. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes
17. Functional analysis of the nucleotide sequence surrounding the cap site for adenovirus type 5 region E1A messenger RNAs
18. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence
19. Adenovirus E1A under the control of heterologous promoters: Wide variation in E1A expression levels has little effect on virus replication
20. Common control of the heat shock gene and early adeno-virus genes: Evidence for a cellular E1A-like activity
21. Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell
22. Emergene of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (DE1 + DE3) during multiple passages in 293 cells
23. Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line
24. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization
25. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted
26. Evaluation of the efficacy and satety of in vitro, adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA
27. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
28. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: Comparison of E2a wild type and E2a deleted vectors
29. Nigh doses of a helper-dependent adenovirus vector yield supraphysiological levels of a 1-antitrypsin with negligible toxicity
30. Toxicological comparison of E2a-deleted and first-generation adenovirus vectors expressing α1-antitrypsin after system delivery
31. A helper-dependent adenovirus vector system: Removal of helper virus by cre-mediated excision of the viral packaging signal
32. Recombinant adenoviruses as vaccines
33. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system
34. Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro
35. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
36. Adenoviridae: The viruses and their replication
37. Genetic analysis of adenoviruses
38. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
39. Identification of two nuclear subclasses of the adenovirus type 5-encoded DNA-binding protein
40. Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression
41. A regulatory system for use in gene transfer
42. Dissection of overlapping functions within the adenovirus type 5 E1A gene
43. Development and application of adenoviral vectors for gene therapy of cancer
44. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted